Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: neuroscience – Page 897

Michael B. Fossel, M.D., Ph.D. (born 1950, Greenwich, Connecticut) was a professor of clinical medicine at Michigan State University and is the author of several books on aging, who is best known for his views on telomerase therapy as a possible treatment for cellular senescence. Fossel has appeared on many major news programs to discuss aging and has appeared regularly on National Public Radio (NPR). He is also a respected lecturer, author, and the founder and former editor-in-chief of the Journal of Anti-Aging Medicine (now known as Rejuvenation Research).

Prior to earning his M.D. at Stanford Medical School, Fossel earned a joint B.A. (cum laude) and M.A. in psychology at Wesleyan University and a Ph.D. in neurobiology at Stanford University. He is also a graduate of Phillips Exeter Academy. Prior to graduating from medical school in 1981, he was awarded a National Science Foundation fellowship and taught at Stanford University.

In addition to his position at Michigan State University, Fossel has lectured at the National Institute for Health, the Smithsonian Institution, and at various other universities and institutes in various parts of the world. Fossel served on the board of directors for the American Aging Association and was their executive director.

Fossel has written numerous articles on aging and ethics for the Journal of the American Medical Association and In Vivo, and his first book, entitled Reversing Human Aging was published in 1996. The book garnered favorable reviews from mainstream newspapers as well as Scientific American and was published in six languages. A magisterial academic textbook on by Fossel entitled Cells, Aging, and Human Disease was published in 2004 by Oxford University Press.

Since his days as a teacher at Stanford University, Fossel has studied aging from a medical and scientific perspective with a particular emphasis on premature aging syndromes such as progeria, and since at least 1996 he has been a strong and vocal advocate of [telomerase therapy]] as a potential treatment of age-related diseases, disorders, and syndromes such as progeria, Alzheimer’s disease, atherosclerosis, osteoporosis, cancer, and other conditions. However, he is careful to qualify his advocacy of telomerase therapy as being a potential treatment for these conditions rather than a “cure for old age” and a panacea for age-related medical conditions, albeit a potential treatment that could radically extend the maximum human life span and reverse the aging process in most people. Specifically, Fossel sees the potential of telomerase therapy as being the single most effective point of intervention in a wide variety of age-related medical conditions. His new book, The Telomerase Revolution, (BenBella, 2015) gives a careful explanation of aging, age-related diseases, and the prospects for intervention, including upcoming human trials.

Facebook: https://www.facebook.com/agingreversed
Twitter: https://twitter.com/Aging_Reversed
Support the Channel: https://goo.gl/ciSpg1
Channel t-shirt: https://teespring.com/aging-reversed

Read more

And you thought needles were scary: Researchers are using scorpion venom to transport drugs to the brain.

The Peptides and Proteins lab at the Institute for Research in Biomedicine (IRB Barcelona) modified the amino acid chain chlorotoxin—present in scorpion venom—to carry medicine across humans’ blood-brain barrier (BBB).

An important mechanism for protecting the brain from harmful substances, the roadblock also prevents medication used to treat neurological diseases and tumors from entering the organ.

Read more

The company-funded animal test was performed to ascertain how neural development is affected by the pesticide chlorpyrifos, which is used on a wide variety of crops around the world, including some 20 EU countries. The test laboratory concluded that there was no such effect, even at high doses.

Academic researchers have examined raw data from a company-funded safety evaluation of the pesticide chlorpyrifos. They discovered an effect on the brain architecture of the exposed laboratory animals at all tested doses, which was not included in the reported conclusions. Karolinska Institutet in Sweden led this independent study, which is published in the scientific journal Environmental Health.

All pesticides must be evaluated in terms of their safety and potential risks for human health before they can officially be approved. Normally the companies that manufacture the products cover the cost of such evaluations and commission test laboratories to perform the necessary animal tests.

Assistant professor Axel Mie at Karolinska Institutet, Christina Rudén at Stockholm University and Philippe Grandjean at Harvard School of Public Health have examined a case in which independent research and company-funded tests deviated, at least in terms of the conclusions drawn in the industry-funded study.

Read more

MORGANTOWN — World-leading brain experts at West Virginia University’s Rockefeller Neuroscience Institute are celebrating the historic breakthrough Alzheimer patients around the global have been waiting for.

“For Alzheimer’s, there’s not that many treatments available despite hundreds of clinical trials over the past two decades and billions of dollars spent,” said Dr. Ali Rezai, a neurosurgeon at WVU who led the team of investigators that successfully performed a phase II trial using focused ultrasound to treat a patient with early stage Alzheimer’s.

The WVU team tested the innovative treatment in collaboration with INSIGHTEC, an Israeli medical technology company. Earlier this year, INSIGHTEC was approved by the U.S. Food and Drug Administration to begin a phase II clinical trial of the procedure and selected the WVU Rockefeller Neuroscience Institute as the first site in the United States for the trial.

Read more